LIPOSOMAL DAUNORUBICIN OVERCOMES DRUG RESISTANCE IN HUMAN BREAST, OVARIAN AND LUNG CARCINOMA CELLS
- 1 January 2002
- journal article
- Published by Taylor & Francis in Journal of Liposome Research
- Vol. 12 (4), 301-309
- https://doi.org/10.1081/lpr-120016196
Abstract
Multi-drug resistance due in part to membrane pumps such as P-glycoprotein (Pgp) is a major clinical problem in human cancers. We tested the ability of liposomally-encapsulated daunorubicin (DR) to overcome resistance to this drug. A widely used breast carcinoma cell line originally selected for resistance in doxorubicin (MCF7ADR) was 4-fold resistant to DR compared to the parent MCF7 cells (IC50 79 nM vs. 20 nM). Ovarian carcinoma cells (SKOV3) were made resistant by retroviral transduction of MDR1 cDNA and selection in vinblastine. The resulting SKOV3MGP1 cells were 130-fold resistant to DR compared to parent cells (IC50 5700 nM vs. 44 nM). Small-cell lung carcinoma cells (H69VP) originally selected for resistance to etoposide were 6-fold resistant to DR compared to H69 parent cells (IC50 180 nM vs. 30 nM). In all three cases, encapsulation of DR in liposomes as Daunoxome (Gilead) did not change the IC50 of parent cells relative to free DR. However, liposomal DR overcame resistance in MCF7ADR br...Keywords
This publication has 23 references indexed in Scilit:
- Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancerCancer Treatment Reviews, 1999
- Simultaneous Activity of MRP1 and Pgp Is Correlated With In Vitro Resistance to Daunorubicin and With In Vivo Resistance in Adult Acute Myeloid LeukemiaBlood, 1999
- Drug resistance in lung cancerCurrent Opinion in Oncology, 1999
- Drug resistance in ovarian cancer: from the laboratory to the clinicPublished by Wolters Kluwer Health ,1998
- Liposomal daunorubicin:in vitro andin vivo efficacy in multiple myelomaHematological Oncology, 1998
- Chemotherapy resistance in ovarian cancer: New molecular perspectivesPublished by Wolters Kluwer Health ,1998
- Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapsed and refractory lymphomaInvestigational New Drugs, 1997
- Multidrug Resistance in Breast Cancer: a Meta-analysis of MDR1/gp170 Expression and Its Possible Functional SignificanceJNCI Journal of the National Cancer Institute, 1997
- Liposomal formulations of cytotoxic drugsSupportive Care in Cancer, 1996
- Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposiʼs sarcomaAIDS, 1996